← board
EDSA
distress 7/10 · high distress / dilution risk$5.57-2%today-70% from 52w high
Lead: acute kidney injury with ARDS
Revenue
pre-revenue
Liquidity
$10M
Runway
1.4 yrs
Shares 1y
+26%
Price & events
+276.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-17.1%
1W
-27.1%
1M
-17.8%
3M
+284.1%
6M
+134.0%
1Y
+18.8%
2Y
-84.6%
5Y
-81.5%
All
Overview
- Market Cap
- $49.53M
- Volume
- 8.07K
- 52 Week Range
- $0.80 – $18.28
- Total Shares
- 8.89M
- Float Shares
- 4.86M
- Short %
- 3.17%
- % Held by Insiders
- 18.66%
- % Held by Institutions
- 39.08%
- RVOL
- 0.07x
- Beta
- 1.05
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- todayconferencedata presentationsecondaryPhase 3paridiprubart · Oral presentation of exploratory AKI data at ERA CongressSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $16 (+193% upside) · 3 analysts
- 2025-11-03HC Wainwright & Co.Buy
- 2025-03-13HC Wainwright & Co.Buy
Competitors — acute kidney injury with ARDS
- none identified
Recent news
- 2026-07-14Edesa Biotech, Inc. SEC Filing (Jul 14, 2026) - Stock Titan
- 2026-07-14Edesa Biotech (EDSA) Declines 2.85% as Shares Approach Key Support Zone - Last Point Support - dars.gov.et
- 2026-07-13Edesa Biotech (EDSA) details $3.5M private placement and 729,241-share resale - Stock Titan
- 2026-07-06Enterprise value to EBIT forward of Edesa Biotech, Inc. – NASDAQ:EDSA - TradingView
- 2026-07-05Edesa Biotech Company Profile & Introduction - Moomoo
- 2026-07-03EDSA Should I Buy - Intellectia AI
- 2026-07-02Edesa Biotech (EDSA) CEO receives 3,378-share RSU grant - Stock Titan
- 2026-06-30Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on Shares - Share Repurchase Impact - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.